Sotiktuzem 6 mg (ducravacitinib)

Adult dose

Take 6 mg of this medication orally once a day.

This medication carries a risk of serious infections and should not be used in patients with severe infections such as pneumonia or coronavirus disease. Patients suspected of having an infection or with a history of chronic infections should carefully consider the risks and benefits of therapy before starting this medication. During treatment, patients should be closely monitored for symptoms of infection, and if an infection occurs, prompt diagnosis and treatment should be sought. If a serious infection is confirmed, the use of this medication should be discontinued until the infection is fully controlled. Use with other powerful immunosuppressants is not recommended, and this medication should not be administered to patients with allergies to the active ingredients or components. Patients with active tuberculosis or serious infections, as well as certain genetically lactose-intolerant patients, should not use this medication. Patients at high risk of infections, those with a history of tuberculosis, those with severely impaired liver function, the elderly, and women who are pregnant or breastfeeding should use this medication cautiously. While taking this medication, side effects such as upper respiratory infections, skin rashes, oral ulcers, and folliculitis may occur, and if muscle pain or myopathy symptoms arise, medical consultation should be sought immediately. Before dosing, it is essential to test for tuberculosis infection, and if latent tuberculosis is present, appropriate treatment should be completed before starting. This medication may increase the risk of malignant tumors, so patients with a history of cancer should consult healthcare professionals thoroughly before use. This medication should not be used with live vaccines, and vaccinations should be completed before starting treatment. Women who are pregnant or breastfeeding should consult healthcare professionals before use, as there is insufficient data on the safety of this medication. Safety and efficacy in pediatric patients have not been established, and the risk of adverse reactions may be increased in the elderly, necessitating caution. In the event of overdose, seek immediate medical attention for appropriate treatment, and keep this medication out of the reach of children.

Serious side effects

• Serious infections (pneumonia, coronavirus disease, etc.), severe allergic reactions, liver abnormalities (jaundice and elevated liver enzymes more than three times), severe edema or urinary problems, serious neurological symptoms (headaches, seizures, confusion), malignant tumors (breast cancer, hepatocellular carcinoma, lymphoma), rhabdomyolysis, breathing difficulties, and other serious infection symptoms.
• If signs of severe infection appear during treatment with this medication, seek immediate attention.

Mild side effects

• Upper respiratory infections, acne-like rashes, increased blood creatine phosphokinase levels, herpes simplex infections, oral ulcers, folliculitis, shingles, elevated liver enzymes, decreased glomerular filtration rate, elevated lipids.
• Most of these adverse reactions are mild to moderate and did not lead to treatment discontinuation.

This medication should be stored in a sealed container that is well-ventilated, at room temperature between 1 and 30 degrees Celsius. This storage method helps maintain the effectiveness of the medication and prevents degradation.

Appearance

Pink film-coated tablets with a round shape that are convex on both sides, printed with BMS 895 6mg on one side in two lines.

Package unit

28 tablets/box [(14 tablets/blister x 2)]